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Abstract
Background: Perceived milk intolerance is a common complaint, and tests for lactose
malabsorption (LM) are unreliable. This study assesses the agreement between diagnostic tests for
LM and describes the diagnostic properties of the tests.
Methods: Patients above 18 years of age with suspected LM were included. After oral intake of
25 g lactose, a combined test with measurement of serum glucose (s-glucose) and hydrogen (H2)
and methane (CH4) in expired air was performed and symptoms were recorded. In patients with
discrepancies between the results, the combined test was repeated and a gene test for lactose non-
persistence was added. The diagnosis of LM was based on an evaluation of all tests. The following
tests were compared: Increase in H2, CH4, H2+CH4 and H2+CH4x2 in expired air, increase in s-
glucose, and symptoms. The agreement was calculated and the diagnostic properties described.
Results: Sixty patients were included, seven (12%) had LM. The agreement (kappa-values) between
the methods varied from 0.25 to 0.91. The best test was the lactose breath test with measurement
of the increase in H2 + CH4x2 in expired air. With a cut-off level < 18 ppm, the area under the
ROC-curve was 0.967 and sensitivity was 100%. This shows that measurement of CH4 in addition
to H2 improves the diagnostic properties of the breath test.
Conclusion: The agreement between commonly used methods for the diagnosis of LM was
unsatisfactory. A lactose breath test with measurement of H2 + CH4x2 in expired air had the best
diagnostic properties.
Background
The population based prevalence of lactose malabsorp-
tion (LM) in Scandinavia is 2-8% [1-3]. The prevalence of
LM is in the same order in subjects with functional gas-
trointestinal disorders (FGID) as in the general popula-
tion, whereas perceived milk and lactose intolerance is
reported by 30-67% of subjects with FGID [2,4-7]. Dietary
advice to subjects with FGID and to those with intolerance
to milk and lactose relies on a valid and reliable diagnos-
tic test for LM. Such a test is not available.
Lactose is an unabsorbable disaccharide hydrolysed by
lactase (lactase-phlorizin hydrolase) in the intestinal
brush border into galactose and glucose that are absorbed.
LM is a failure to hydrolyse lactose. In adults the most
common cause is a genetic defect with lack of intestinal
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bacteria to produce gas (hydrogen (H2) and methane
(CH4)) and short chain fatty acids. Clinical manifesta-
tions of LM are abdominal pain/discomfort, borborygmi,
bloating, flatulence and diarrhoea [2,8]. In subjects with
LM, symptoms depend on the amount of lactose. Most
people with LM can, due to colonic adaptation to regular
lactose ingestion, ingest up to 6-12 g lactose (120 - 240
mL milk) without developing symptoms [9-11].
Commonly used tests for the diagnosis of LM are based on
an exaggerated increase in H2 and/or CH4 in the expired
air after intake of lactose, or an inappropriate increase in
serum glucose (s-glucose). Other tests are assessment of
lactase activity in jejunal biopsies, a test for genetic defects
[12,13], and registration of symptoms after intake of lac-
tose [14]. Recently, the Rome Consensus Conference pub-
lished a review of the methodology and indications of H2-
breath testing in gastrointestinal diseases [15]. No "gold
standard" is available for the diagnosis of LM and breath
tests with measurement of volatile compounds and other
gases (mainly CH4) were encouraged [15]. There are few
comparisons between the tests and no agreement upon
which one is the best.
The aims of this study were to assess the agreement
between commonly used diagnostic methods for LM
(breath test, s-glucose and symptoms), describe the diag-
nostic properties of the methods and establish the best
method and cut-off levels for clinical use.
Methods
Subjects
Patients with intolerance to milk or dairy products and/or
unexplained abdominal discomfort consistent with LM
seen in one outpatient gastroenterological unit were
invited to participate in the study. Exclusion criteria were
age below 18 years, insufficient understanding of written
instructions, intake of antibiotics the last two weeks and a
previous diagnosis of LM. Age, sex, Body Mass Index
(BMI), ethnicity, smoking habits, the patients' reaction to
milk and dairy products, and current and past diseases
were noted.
Methods
The initial diagnostic test for LM was a combined breath-
and s-glucose test after intake of 25 g lactose. The test was
performed at the hospital in the morning. Prior to the test
the patients were on a low fibre diet for 48 hours, and they
were not allowed to eat, drink or smoke the last 12 hours
before the test. Physical activity, except for the limited
activity necessary to reach the hospital, was prohibited in
the morning before the test. H2 and CH4 were measured
in the expiratory air before, and 30, 60, 120, and 180 min-
utes after intake of lactose with a stationary gas chromato-
graph (SC MicroLyzer, QuinTron Instrument Co,
Milwaukee, Wisc., USA). Alveolar air was collected using
a Y-piece device (QuinTron AlveoSampler) after 10 sec-
onds' expiration, analysed immediately after the collec-
tion and corrected for alveolar CO2. Samples for s-glucose
were taken before, and 15, 30, 60, and 90 minutes after
intake of lactose. An increase in H2 ≥20 ppm (parts per
million) compared to the lowest measured value, an
increase in CH4 ≥12 ppm compared to the value meas-
ured before the intake of lactose, or an increase in the sum
of H2 and CH4 ≥15 ppm was considered as a diagnostic
test for LM, as was increase in s-glucose < 1.1 mmol/L
from baseline. If the s-glucose test and the breath test had
concurrent outcomes (both were normal or abnormal),
the patient was classified as not having LM or having LM.
Twenty-four hours after the first combined breath- and s-
glucose tests the patients filled in a questionnaire which
was returned to the hospital. They were asked about the
presence of abdominal symptoms during and for 24
hours after the combined test. If abdominal symptoms
were present, they answered three additional questions: 1)
When did the symptoms start? (during the test or 0-2 h, 2-
4 h, 4-8 h, > 8 h after the test) 2) What type of symptoms
have you experienced? (abdominal pain/discomfort, bor-
borygmi, bloating, diarrhoea, or constipation) and 3)
How long did the symptoms last? (0-2 h, 2-4 h, 4-8 h, >8
h). In accordance with a previous study, symptoms start-
ing within 5 h after intake of lactose and lasting for more
than 2 h were classified as "Early and Long Lasting" (ELL)
[2].
In cases of discrepancies between the initial breath test
and the s- glucose test, the combined test was repeated
without registration of symptoms, and a diagnostic gene
test (Lactase C-13910T, chromosome 2q21-22) was
added [12,13]. The gene tests were analyzed at the Hor-
mone Laboratory, Aker University Hospital, Oslo, Nor-
way. In patients with discrepancies between the breath-
and the s-glucose test at the first combined test, a total of
five tests were available: Two sets of breath tests, two sets
of s-glucose tests and one gene test. The presumed correct
diagnosis was based on an evaluation of all tests. If three
or more tests were abnormal, it was concluded that the
patient had LM.
Because the synthesis of CH4 consumes large amounts of
H2, an increase in CH4 in the expiratory air reduces the
production of H2. Therefore, the diagnostic properties of
the increase in H2 + CH4x2 were studied in addition to
the conventional variables (H2, CH4, H2+CH4, s-glucose
and symptoms). The diagnostic properties of the gene test
are not reported because of the limited number of analy-
ses. The results of all tests (the first and the repeated ones)Page 2 of 7
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the test variables.
In search of optimal cut-off levels for screening purposes,
high sensitivity and therefore a lower specificity, was pre-
ferred, with further diagnostic examinations in subjects
with positive tests.
Statistical analyses
Comparisons between the groups were analysed with
Mann-Whitney test and Fisher's exact test, and agreement
with kappa statistics. Receiver Operating Characteristic
(ROC) curves describe the diagnostic properties of the var-
iables. SPSS version 14.0 with exact tests was used for the
analyses. P-values < 0.05 were considered statistically sig-
nificant, and 95% confidence intervals (CI) were calcu-
lated for the main variables.
Ethics
The study was conducted according to the Declaration of
Helsinki, and approved by the Regional Committee for
Medical Research Ethics, Trondheim, Norway and Norwe-
gian Social Science Data Services. Written informed con-
sent was given by all participants before inclusion.
Results
Sixty patients were included. Five patients had LM and 45
had not after the first combined breath- and s-glucose test
(both tests were clearly positive or negative). In ten
patients with discrepancies between the blood- and
breath tests, the combined test was repeated and the gene
test performed. Two of these ten patients were classified as
having LM (they had three positive and two negative tests)
and eight were normal (four patients had two positive and
three negative tests, and four patients had one positive
and four negative tests). The gene test was positive in one
of the two patients with LM, and negative in eight patients
without LM. In total, seven patients (12%) were classified
as having LM.
Table 1 gives the characteristics of patients with and with-
out LM. Except for a lower BMI in patients with LM, there
were no significant differences between the groups. Four
patients had organic diseases in clinical remission (three
had ulcerative colitis and one Crohn's disease), none of
them had LM. Fifty-six patients had functional bowel dis-
orders. In patients with and without LM the increase in H2
(mean and range) were 59 ppm (0-170) and 5 ppm (0-
52) respectively, increase in CH4 were 3 ppm (0-13) and
1 ppm (0-20) respectively, increase in H2 + CH4 were 62
ppm (13-170) and 6 ppm (0-52) respectively, increase in
H2 + CH4x2 were 65 ppm (18-170) and 7 ppm (0-52)
respectively, and increase in blood glucose were 0.7
mmol/L (0.1-1.5) and 2.0 mmol/L (0.7-4.6) respectively.
One patient did not fill in the symptom questionnaire
after the lactose test, and one patient did not report exact
indication of time, which made evaluation of ELL impos-
sible. Table 2 gives the symptoms in the groups with and
without LM. Presence of any ELL symptom had the best
diagnostic properties, and pain/discomfort-ELL, borbo-
rygmi-ELL, and bloating-ELL were all statistically signifi-
cantly related to LM.
Table 3 gives the results of the receiver operating charac-
teristics curves (ROC) analyses. The breath test with meas-
urement of H2 + CH4x2 was the best one. The best cut-off
levels (normal values) for the increase in H2+CH4x2,
H2+CH4, H2, and s-glucose were considered to be < 18
ppm, <17 ppm, <16 ppm, and > 0.9 mmol/L respectively.
Table 4 gives the agreement between the test variables
with these cut-off levels. With this cut-off level, the sensi-
tivity of H2+CH4x2 was 100%.
Table 5 gives the sensitivity, specificity, positive and nega-
tive predictive values, accuracy and likelihood ratio (LR+
and LR-) for the increase in gas and s-glucose with differ-
ent cut-off levels (normal values) and for the presence of
any symptom-ELL.
Discussion
This study clearly demonstrates the unsatisfactory agree-
ment between commonly used diagnostic tests for LM.
The major methodological problem is the lack of a "gold
Table 1: Characteristics of the patients with and without lactose malabsorption (LM).
Patients' characteristics LM Not LM Statistics
Number of subjects 7 53
Male 1/7 (14%) 16/53 (30%) ns (p = 0.66)
Age in years 46 (35-55) 36 (18-71) ns (p = 0.15)
Scandinavian origin 7/7 (100%) 52/53 (98%) ns (p = 1.00)
Body Mass Index (BMI) 21.1 (20.1-27.3) 24.8 (18.5-37.2) p = 0.027
Organic bowel disease 0/7 (0%) 4/53 (8%) ns (p = 1.00)
Abdominal discomfort after intake of milk/dairy products 4/6 (67%) 43/51 (84%) ns (p = 0.28)
Daily smoker 1/7 (14%) 17/53 (32%) ns (p = 0.66)
The results are given as number of patients (percentage in brackets) or median (range in brackets).Page 3 of 7
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assessment of lactase activity is an unreliable method due
to the irregular dissemination of lactase in the intestine,
the available genetic test does not detect all genetic disor-
ders related to LM and does not diagnose secondary LM,
breaths tests are highly dependent on the microflora
throughout the gut, and serum glucose depends on the
glucose absorption and metabolism [15]. Therefore this
study assesses primarily the agreement between the test
variables. But because assessment of agreement between
tests requires a positive or negative result of the test, we
had to diagnose LM in each patient. The final diagnosis of
LM was based on an overall evaluation of all tests per-
formed in each subject. This is the only applicable method
when no formal "gold standard" is available. When the
diagnosis was established, the best cut-off levels (normal
values) for each of the continuous variables were chosen.
A high sensitivity was preferred to avoid false negative
results at the expense of a lower specificity.
Lactose breath test with measurement of H2+CH4x2 was
judged as the best test. It was superior to H2+CH4 because
of better sensitivity and a somewhat higher area under the
ROC-curve (tables 3 and 5). The sensitivity and specificity
was 100% with cut-off levels (normal values) < 18 ppm
and < 53 ppm respectively. Results in the range from 18
ppm to 52 ppm render further tests necessary to obtain a
conclusive diagnosis. The agreement between H2 + CH4
and H2+CH4x2 was, as expected, very good because most
subjects with LM predominantly produce H2, and the var-
iables are slight modifications of each other. Nevertheless,
H2 + CH4x2 seem to be preferable in clinical use and have
satisfactory diagnostic properties.
Breath tests with measurement of only H2 have been
judged as reliable tests for LM [16,17]. The recently pub-
lished Rome Consensus Conference report states that
measurement of breath CH4 excretion is not currently rec-
ommended to improve the diagnostic accuracy of the H2
breath test due to lack of evidence, and that further studies
on other gases (mainly CH4) than H2 should be encour-
aged [15]. In this study, the agreement between H2 and
any combination of H2 and CH4 was very good, but the
lower sensitivity of H2 only made it inferior to the combi-
nation of H2 + CH4x2. Since about 30% of the adult pop-
ulation is so-called CH4-producers and the
methanogenesis consumes large quantities of H2 to pro-
duce CH4, it is reasonable to measure CH4 in addition to
H2. This study showed that measurement of CH4 in addi-
tion to H2 increased the diagnostic accuracy of the breath
test and that H2 + CH4x2 was the best one despite the fact
that the concentration of CH4 is variable both in fasting
conditions and after meals [18].
S-glucose is an alternative to breath test. The agreement
with the breath test was modest and clinically unsatisfac-
tory, but the diagnostic properties (sensitivity, specificity,
PPV, NPV, and LR) were identical with that of H2 (table
5). The poor agreement and identical diagnostic proper-
ties are the result of different diagnostic classification into
health and disease of the two methods. Since no gold
standard is at hand it is impossible to judge between
them, but because of the low specificity of s-glucose and
lower area under the ROC-curve we conclude in accord-
ance with other publications that it is inferior to breath
test with measurement of H2 or H2 + CH4x2 (tables 3 and
5) [17,19].
Table 2: Symptoms after intake of lactose in patients with and 






Pain/discomfort all 5/7 (71%) 21/52 (40%) p = 0.223
Pain/discomfort-ELL 5/7 (71%) 8/52 (15%) p = 0.004
Borborygmi all 5/7 (71%) 25/52 (48%) ns (p = 0.424)
Borborygmi-ELL 5/7 (71%) 8/51 (16%) p = 0.005
Bloating all 5/7 (71%) 24/52 (46%) ns (p = 0.254)
Bloating-ELL 5/7 (71%) 8/51 (16%) p = 0.005
Diarrhoea all 4/7 (57%) 16/52 (31%) ns (p = 0.213)
Diarrhoea-ELL 3/7 (43%) 4/51 (8%) p = 0.032
Constipation all 0/7 (0%) 4/52 (8%) ns (p = 1.00)
Constipation-ELL 0/7 (0%) 4/52 (8%) ns (p = 1.00)
Any symptom 6/7 (86%) 32/52 (62%) ns (p = 0.40)
Any symptom-ELL 6/7 (86%) 11/51 (22%) p = 0.002
ELL (= "Early and Long Lasting"): Symptoms starting within 5 h after 
intake of lactose and lasting for more than 2 h. Any symptom-ELL = 
Any "Early and Long Lasting" symptom.
The results are given as number of patients with proportions in 
brackets.
Table 3: The results of the receiver operating characteristics curve (ROC) analyses for the test variables.
Test variables Area under ROC-curve 95% CI Statistics
H2+CH4x2 0.976 0.945-1.007 p < 0.001
H2+ CH4 0.969 0.931-1.007 p < 0.001
s-glucose 0.924 0.836-1.013 p < 0.001
H2 0.872 0.688-1.055 p < 0.001
CH4 0.638 0.424-0.851 ns (p = 0.185)Page 4 of 7
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used as a simple test for LM [14]. Evaluation of the onset,
severity and duration of symptoms for 8 hours has been
recommended [15]. This study shows in accordance with
previous reports, that symptoms in general are highly
unreliable and unfit for clinical use [2]. Symptoms ques-
tionnaires and symptom based criteria such as "Early and
Long Lasting (ELL)-symptoms" have better diagnostic
properties [2,16]. In this study ELL-symptoms were supe-
rior to unspecified symptoms after intake of lactose. These
findings are in agreement with the Rome Consensus Con-
ference that symptoms should be evaluated during and
for some hours after the test, and that onset and duration
are of importance [15]. But even ELL-symptoms showed
unacceptable diagnostic properties and poor agreement
with any of the other test (table 4 and 5). This fits with the
clinical observation that the prevalence of perceived lac-
tose intolerance, which is also related to visceral hypersen-
sitivity, is significantly higher than that of LM, and that
subjects with LM can consume a variable but limited
amount of lactose without developing symptoms
[9,11,20].
In this study the genetic test was performed in only ten
subjects with discrepancies at the first combined test and
the results therefore give limited information about the
usability of the test. The test is probably highly indicative
of lactase non-persistence in adults [12,13]. But the fact
that LM might be due to other genetic abnormalities and
organic disorders in the gastrointestinal tract limits the
clinical utility of the test [21,22].
The selection criteria were pragmatic and based on per-
ceived milk intolerance or symptoms judged as possible
LM by the doctor. The selection was not strictly scientific,
but according to everyday practice. The prevalence of LM
was rather low despite the fact that most patients had
symptoms related to intake of milk or lactose and were
referred with suspected LM. This is in accordance with
other studies in Scandinavia showing a low prevalence of
LM both in the general population and in patients with
FGID [2,3]. A somewhat lower BMI was the only clinical
characteristic of subjects with LM, and has also been
reported in other trials [23].
Performance of the breath tests varies. In this study, the
tests were performed according to recently published
guidelines concerning devices for breath sampling, sta-
tionary and immediate analyses, prolonged expiration
and correction for alveolar CO2, use of antibiotics, diet,
cigarette smoking and physical exercise [15]. However, no
mouth washing was performed, and colonic clearing was
not sufficiently taken into account, but was never per-
formed in close relation to the test. A three-sample H2
breath test is favourable compared to a two-sample [24].
The five-sample test used in this trial strengthens the
results. The length of the test was three hours; 4 hours
have been recommended because some subjects have a
slow transit [15]. In all, it is unlikely that these minor
deviations from the recently published recommendations
have had any significant influence on the results. Also the
dose of lactose varies. Twenty-five gram lactose (equiva-
lent to 500 mL milk), the dose used in this trial, seems rea-
sonable and is the recommended dose [15]. This amount
Table 4: Agreement between the test variables with the best cut-off values. 
Variables H2 +CH4x2 <18 ppm H2 + CH4 <17 ppm H2 < 16 ppm s-glucose > 0.9 mmol/L
H2 + CH4 < 17 ppm 0.91 (p < 0.001) ----- ----- -----
H2 < 16 ppm 0.81 (p < 0.001) 0.90 (p < 0.001) ----- -----
s-glucose > 0.9 mmol/L 0.44 (p = 0.001) 0.50 (p < 0.001) 0.46 (p = 0.001) -----
Any symptom-ELL 0.38 (p = 0.002) 0.43 (p < 0.001) 0.41 (p < 0.001) 0.25 (p = 0.032)
The results are given as kappa values with statistics (p-values) in brackets.
Table 5: The diagnostic properties (sensitivity, specificity, positive and negative predictive values, accuracy and likelihood ratios (LR)) 
for the variables in the study with different cut-off levels (normal values). 
Variable Normal value Sensitivity Specificity PPV NPV Accuracy LR + LR-
H2 + CH4x2 <53 ppm 44.4% 100% 100% 92.4% 92.9% Inde-finite 0.56
H2 + CH4x2 <18 ppm 100% 90.2% 60% 100% 91.4% 10.2 0
H2 + CH4 <17 ppm 88.9% 91.8% 61.5% 98.2% 91.4% 10.8 0.12
H2 <16 ppm 77.8% 93.4% 63.6% 96.6% 91.4% 11.9 0.24
s-glucose-increase >0.9 mmol/L 77.8% 93.4% 63.6% 96.6% 91.4% 11.9 0.24
Any symptom-ELL Absent 85.7% 78.4% 35.3% 97.6% 79.3% 4.0 0.18
The results are based on all performed tests.Page 5 of 7
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the range of normal consumption [9,11,25].
Practical and correct dietary advice to patients with FGID
and food intolerance is impossible without valid and reli-
able tests for food intolerance. Such tests are by and large
missing. Patients with food intolerance often make
unnecessary changes in the diet which for some result in
malnutrition [6,26]. Further improvement of the diagnos-
tic armamentarium for food intolerance is desired to
improve dietary treatment.
Conclusion
This trial shows unsatisfactory agreement between com-
monly used diagnostic tests for LM. The test with the best
diagnostic properties was lactose breath test with 25 g lac-
tose and measurement of the increase in the sum of H2
and CH4x2. The area under the ROC-curve was 0.976,
sensitivity was 100% with a cut-off level < 18 ppm, and
specificity was 100% with a cut-off level < 53 ppm. Results
in the range from 18 ppm to 52 ppm render further tests
necessary to obtain a conclusive diagnosis.
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